Nordion's constantly evolving business will soon be without proprietary pharma, as the company has agreed to ship out its targeted therapies business for $200 million.
Turns out there was some truth behind the rumors that 3i was shopping the anti-infectives company Xellia.
Novo A/S, the Danish holding company of and major shareholder in Novo Nordisk, said today it is pursuing a new piece of its investment strategy focused on more well-established companies as it announced the $700 million purchase of anti-infectives maker Xellia Pharmaceuticals.
As the dust settles around Actavis' announced buyout of Warner Chilcott, it's time to dig into some of the nitty-gritty details about "New Actavis." For instance, which of Warner's top people will stick around--and if they don't, how much severance might they collect on the way out? And just how big is the tax cut Actavis expects from making the deal?
Shire ($SHPG) is a perennial entry on everybody's favorite M&A target list. Now, according to the Daily Mail , Shire is putting its ducks in a row for a potential "special dividend" to counter any takeover interest. Word is, an £11 billion hostile bid is coming.
Actavis and Warner Chilcott have struck a deal. And it's bigger than the $5 billion-or-so that was bandied about while the companies negotiated. About $3 billion bigger, in fact: According to Actavis, the company will acquire Warner in a stock swap worth $8.5 billion.
In a dealmaking frenzy, cash-rich Elan has agreed to pay up to $693 million for a biotech company focused on rare diseases, picked up a big share of a start-up specialty pharma company based in Dubai, spun out its sole remaining clinical asset into a new company with $90 million in financing and set up an $800 million debt offering to help keep the deals coming.
Quest Diagnostics is on a buying spree to grow its testing business, and now the company has signed a deal to buy the toxicology and clinical laboratory segment of health insurance giant Humana.
Actavis has suddenly become the belle of the ball. The Wall Street Journal reports that Novartis is now entertaining a $16 billion bid for the generics maker after a $13 billion offer from Valeant and a $15 billion bid from Mylan both fell flat.
We thought Actavis had a love triangle going with potential merger partners Warner Chilcott and Valeant Pharmaceuticals, as an analyst dubbed it earlier this week. Now, news emerges that it's more like a love quadrangle, with rejections on two sides.